Oral aspergillosis in compromised patients.
Sugata
T
T
Myoken
Y
Y
Kyo
T
T
Fujihara
M
M
D000328:Adult; D000368:Aged; D001228:Aspergillosis / Q000209:etiology* / Q000276:immunology / Q000473:pathology / Q000517:prevention & control; D018890:Chemoprevention; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications*; D006801:Humans; D016867:Immunocompromised Host; D017964:Itraconazole / Q000627:therapeutic use; D015456:Leukemia, Biphenotypic, Acute / Q000150:complications; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications; D015470:Leukemia, Myeloid, Acute / Q000150:complications; D008223:Lymphoma / Q000150:complications; D008297:Male; D008875:Middle Aged; D009059:Mouth Diseases / Q000209:etiology* / Q000276:immunology / Q000382:microbiology / Q000473:pathology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications
D017964:Itraconazole